Comparison of Glucovance to Insulin for Diabetes During Pregnancy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00371306 |
|
Recruitment Status : Unknown
Verified April 2007 by Regional Obstetrical Consultants.
Recruitment status was: Recruiting
First Posted : September 4, 2006
Last Update Posted : April 20, 2007
|
Sponsor:
Regional Obstetrical Consultants
Information provided by:
Regional Obstetrical Consultants
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Pregnant women with gestational or Type 2 diabetes who require medication are placed in one of two groups: Insulin injections or Glucovance (oral administration). Blood glucose is checked 5 times per day, and medication adjusted by perinatologist according to glucose levels. The hypothesis is that patients will have similar or improved blood glucose control on an oral agent as compared to control on insulin.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Gestational Diabetes Type 2 Diabetes Pregnancy | Drug: Insulin versus glucovance (glyburide/metformin) | Not Applicable |
According to ACOG guidelines, patients between 24 and 28 weeks gestation will be screened with a 1 hour glucose tolerance test (GTT) by their obstetrician. Those with elevated glucose levels will undergo a 3 hour GTT. According to routine OB standards, if the blood glucose is elevated on 2 or more of 4 parameters during this test (> 95 fasting, > 180 at 1 hour, > 155 at 2 hours, >140 at 3 hours), the patient will begin receiving dietary therapy using ADA guidelines. If blood glucose levels remain 20% above a fasting of 90 & post parandial of 120 with diet alone during a period of 1-3 weeks after diagnosis, the patient will be invited to participate in this study. Type 2 diabetics who have been diagnosed prior to pregnancy will also be included. These patients may enroll in the study prior to 24 weeks gestation, entering at the time of referral. Patients who give consent for participation will be randomly assigned to either insulin therapy (the usual standard of care), or to oral Glucovance therapy (the experimental group). Glucovance will be started at 1.25mg/250mg BID. NPH & regular Insulin will be started on a 1unit/kg basis BID. Both groups will receive care according to the current standard for gestational diabetics and pregnant Type 2 diabetics. The perinatologist and diabetes educator will evaluate the blood glucose record and assess the patient's adherence to the ADA diet weekly and will determine when the insulin or Glucovance needs to be increased. If the patients in the Glucovance group continue to be poorly controlled with 4 tablets/day (5mg/500mg), the therapy will be continued and insulin will be added to the management. Statistical analysis will compare the two groups for myriad factors including vaginal versus operative deliveries, hemoglobin A1C, fructosamine, and glucose at delivery, infant birth weight, infant complications, initial infant blood glucose.
| Study Type : | Interventional (Clinical Trial) |
| Enrollment : | 200 participants |
| Allocation: | Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | Single |
| Primary Purpose: | Treatment |
| Official Title: | A Comparison of Glucovance (Glyburide and Metformin) to Insulin Therapy for the Treatment of Gestational Diabetes and Adult Onset Diabetes in Pregnancy |
| Study Start Date : | September 2002 |
| Estimated Study Completion Date : | September 2008 |
Primary Outcome Measures :
- Maternal hemoglobin A1C at delivery
- Maternal fructosamine at delivery
- Maternal glucose at delivery
Secondary Outcome Measures :
- Mode of delivery
- Infant birth weight
- Infant initial glucose
- Infant complications
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:Gestational diabetes by ACOG definition or Type 2 diabetes in pregnancy Hyperglycemia despite following ADA diet English or Spanish speaking -
Exclusion Criteria:Already requiring Insulin Serum creatinine > 1.3 or creatinine clearance < 75ml/minute Liver disease
-
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00371306
Contacts
| Contact: Lorrie A Mason, MSN | 423 664-4460 | lorrie@rocob.com |
Locations
| United States, Tennessee | |
| Regional Obstetrical Consultants | Recruiting |
| Chattanooga, Tennessee, United States, 37403 | |
Sponsors and Collaborators
Regional Obstetrical Consultants
Investigators
| Principal Investigator: | Joseph H Kipikasa, MD | Regional Obstetrical Consultants; UT Chattanooga OB-GYN Department |
| ClinicalTrials.gov Identifier: | NCT00371306 |
| Other Study ID Numbers: |
02-078 |
| First Posted: | September 4, 2006 Key Record Dates |
| Last Update Posted: | April 20, 2007 |
| Last Verified: | April 2007 |
Keywords provided by Regional Obstetrical Consultants:
|
Diabetes Pregnancy |
Additional relevant MeSH terms:
|
Diabetes, Gestational Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Pregnancy Complications Metformin Glyburide Hypoglycemic Agents Physiological Effects of Drugs |